Rezvilutamide

DB19133InvestigationalSmall molecule

Rezvilutamide is under investigation in clinical trial NCT05956639 (Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in Mhspc).

Mechanism: Pharmacologically active on Androgen receptor
Curator reviewed
Formula / weight: C₂₂H₂₀F₃N₃O₄S · 479.47 g/mol (avg)
Also known as: 4-(3-(4-((s)-2,3-dihydroxypropoxy)phenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile · Benzonitrile, 4-(3-(4-((2s)-2,3-dihydroxypropoxy)phenyl)-4,4-dimethyl-5-oxo-2-thioxo-1-imidazolidinyl)-2-(trifluoromethyl)-
Code names: SHR-3680

Resolves to

Compound

UNII70FJN2AW22CAS1572045-62-5ChEMBLCHEMBL4650276

Structure

InChIKeyKRBMOYIWQCZVHA-INIZCTEOSA-NSMILESCC1(C)N(C(=S)N(C1=O)C1=CC=C(C#N)C(=C1)C(F)(F)F)C1=CC=C(OC[C@@H](O)CO)C=C1

Targets

P10275AR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

37Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rezvilutamide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account